With 0.51 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.8 million shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $9.4 whereas the lowest price it dropped to was $9.09. The 52-week range on WEAV shows that it touched its highest point at $17.63 and its lowest point at $8.50 during that stretch. It currently has a 1-year price target of $14.14. Beta for the stock currently stands at 1.85.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of WEAV was down-trending over the past week, with a drop of -6.39%, but this was down by -17.51% over a month. Three-month performance dropped to -17.29% while six-month performance fell -38.54%. The stock gained 0.89% in the past year, while it has lost -42.90% so far this year. A look at the trailing 12-month EPS for WEAV yields -0.41 with Next year EPS estimates of 0.14. For the next quarter, that number is 0.00. This implies an EPS growth rate of 9.23% for this year and 158.68% for next year. EPS is expected to grow by 84.01% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 5.67%.
Float and Shares Shorts:
At present, 74.91 million WEAV shares are outstanding with a float of 64.22 million shares on hand for trading. On 2025-05-30, short shares totaled 2.72 million, which was 361.99997999999994 higher than short shares on 1745971200. In addition to Mr. Brett T. White as the firm’s CEO & Director, Mr. Joseph David McNeil serves as its Chief Revenue Officer.
Institutional Ownership:
Through their ownership of 0.88894 of WEAV’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, WEAV reported revenue of $55809000.0 and operating income of -$9320000.0. The EBITDA in the recently reported quarter was -$4572000.0 and diluted EPS was -$0.12.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for WEAV since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With WEAV analysts setting a high price target of 17.0 and a low target of 11.0, the average target price over the next 12 months is 14.14286. Based on these targets, WEAV could surge 87.02% to reach the target high and rise by 21.01% to reach the target low. Reaching the average price target will result in a growth of 55.59% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.05275375 being high and $0.04142725 being low. For WEAV, this leads to a yearly average estimate of $0.042203. Based on analyst estimates, the high estimate for the next quarter is $0.02 and the low estimate is $0.01. The average estimate for the next quarter is thus $0.01.
